Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study

Luis Téllez1 | Eugenia Sánchez Rodríguez1 | Enrique Rodríguez de Santiago1 | Laura Llovet2 | Ana Gómez-Outomuro3 | Fernando Díaz-Fontenla4 | Patricia Álvarez López5 | María García-Eiz6 | Carla Amaral7 | Yolanda Sánchez-Torrijos8 | José Ignacio Fortea9 | Carlos Ferre-Aracil10 | Manuel Rodríguez-Perálvarez11 | Marta Abadía12 | Judith Gómez-Camarero13 | Antonio Olveira12 | José Luis Calleja10 | Javier Crespo8 | Manual Romero | Manuel Hernández-Guerra7 | Marina Berenguer6 | Mar Riveiro-Barciela5 | Magdalena Salcedo4 | Manuel Rodríguez3 | María Carlota Londoño2 | Agustín Albullos1

1Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universidad de Alcalá, Madrid, Spain
2Liver Unit, Hospital Clínic, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universidad de Barcelona, Barcelona, Spain
3Liver Unit, Division of Gastroenterology and Hepatology, Hospital Universitario Central de Asturias, ISPA, Universidad de Oviedo, Oviedo, Spain
4Liver Unit, Hospital General Universitario Gregorio Marañón, IISGM. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universidad Complutense de Madrid, Madrid, Spain
5Liver Unit, Internal Medicine Department, Hospital Universitari Vall d’Hebron, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universidad de Barcelona, Barcelona, Spain
6Department of Gastroenterology and Hepatology, Hospital Universitario La Fe, IISLaFe, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universidad de Valencia, Valencia, Spain
7Liver Unit, Hospital Universitario de Canarias, CIBICAN, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universidad de La Laguna, Tenerife, Spain
8Department of Gastroenterology and Hepatology, Hospital Universitario Virgen del Rocío, IBIS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universidad de Sevilla, Sevilla, Spain
9Department of Gastroenterology and Hepatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universidad de Cantabria, Santander, Spain
10Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro, IISPH, Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
11Department of Hepatology and Liver Transplantation, Hospital Universitario Reina Sofía, IMIBIC, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Córdoba, Spain
12Department of Gastroenterology and Hepatology, Hospital Universitario La Paz, IDIPAZ, Universidad Autónoma de Madrid, Madrid, Spain
13Department of Gastroenterology and Hepatology, Complejo Asistencial Universitario de Burgos, Burgos, Spain

Luis Téllez and Eugenia Sánchez Rodríguez share co-first authorship.

The Handling Editor for this article was Professor Gideon Hirschfield, and it was accepted for publication after full peer-review.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Autoimmune hepatitis (AIH) is an immune-mediated necro-inflammatory liver disease affecting all ages, genders and ethnic groups.\(^1\)\(^,\)\(^2\) Clinically, the spectrum of presentation at diagnosis is broad, ranging from mild subclinical disease to an acute disease course in 20%, even leading to fulminant liver failure.\(^3\)\(^,\)\(^4\) Acute severe-AIH (AS-AIH) has been defined as acute onset of jaundice (<30 days) and an international normalised ratio (INR) ≥1.5 in patients without known chronic liver disease.\(^5\)\(^,\)\(^6\) AS-AIH has been scarcely characterised and its actual prevalence might have been underestimated owing to the difficulty of achieving an accurate diagnosis.\(^4\)\(^,\)\(^5\) In 50%-60% of patients, AS-AIH progress to acute liver failure (ALF), which has a dismal prognosis with death rates as high as 20% and a need for liver transplantation in 20%.\(^5\)\(^,\)\(^9\)\(^,\)\(^10\)\(^,\)\(^11\) The risk of this progression is unknown, and there is much controversy over the factors that can modify outcomes, including treatments. Current guidelines recommend a trial with corticosteroids with subsequent reference to emergency liver transplantation in case of failure to improve within the first 7-14 days.\(^2\)\(^,\)\(^3\) This approach means that liver transplantation could be unnecessarily delayed and therapy prolonged in patients unlikely to respond to corticosteroids. Further, immunosuppression could increase the risk of infection and compromise prognosis and liver transplantation.\(^12\)\(^,\)\(^13\)\(^,\)\(^14\) A recent multicentric French study has shown the accuracy of the response to 3-7 days corticosteroids to predict liver transplantation or death in patients with AS-AIH and has provided a new score (SURFASA score) to identify non-responders.\(^15\) We propose that a model able to identify factors that can be assessed as soon as possible to predict the response to corticosteroids will be crucial for decision-making.

The aims of our study were, therefore: (i) to assess whether corticosteroids improve prognosis and (ii) to identify factors at presentation and early during therapy that could serve to predict the individual response to this therapy.

## 2 | PATIENTS AND METHODS

### 2.1 | Study design and patients

This retrospective cohort study was conducted at 13 Spanish tertiary centres from January 2002 to January 2019. All consecutive adults diagnosed with AS-AIH were included. AS-AIH was defined as (i) acute hepatic dysfunction (<3 months) as confirmed by an INR ≥1.5 at the time of presentation; (ii) no known history of chronic liver disease, and (iii) fulfilling simplified International Auto-Immune Hepatitis Group (IAHG) criteria for a diagnosis of “probable” or “definite” AIH.\(^8\) Patients with an INR ≥1.5 and hepatic encephalopathy were subclassified as having ALF-AIH.\(^5\) A favourable corticosteroid response was defined as the absence of death or liver transplantation within 90 days...
of admission. The study protocol adhered to the principles of the Declaration of Helsinki and was approved by the Ethics Committees for Clinical Research of all the participating centres (Institutional review board code: HRC 070/18). The study was performed according to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement. The need for written informed consent was waived due to the retrospective nature of the study.

### 2.2 Study outcomes, procedures and variables

Our primary outcome was a composite of death or liver transplantation within 90 days of hospital admission. Secondary outcomes included histological markers of severity and the risk of infection during the first 90 days. A dedicated database was created and demographic, clinical and laboratory information was retrospectively obtained from paper and electronic records from the in-hospital, emergency department and primary healthcare databases at each centre. Patients were screened to rule out other causes of ALF, including Wilson’s disease. We considered the results of viral serology with immunoglobulin G and M (IgG and IgM) for Hepatitis A, B and E, Herpes simplex, Epstein–Barr virus and Cytomegalovirus (CMV), as well as the determination of hepatitis C RNA. All potenti ally hepatotoxic drugs administered within the previous 3 months were evaluated to rule out drug-induced liver injury. Abdominal ultrasound was performed in all patients. Ascites was considered present from grade 1 (i.e., only detectable by ultrasound examination).

Serum IgG and specific AIH-related antibodies were measured in all patients. Laboratory parameters of serum creatinine, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), INR and platelet count were recorded at admission, at initiation and at days 3, 7 and 14 of corticosteroid therapy. Clinically relevant events (ascites and hepatic encephalopathy) were assessed at each of the established time points, and the model for end-stage liver disease (MELD) score was calculated. Diagnosis of infection was based on clinical, radiological and laboratory findings, as detailed in supporting information. Finally, histological information indicative of AIH (portal lymphoplasmacytic infiltration, interface hepatitis, central venulitis, hepatocyte rosettes and emperipolesis) was obtained from liver biopsies and explants. Liver fibrosis was graded 0–4 following the METAVIR score; grades 3 and 4 were taken to denote severe fibrosis. Necrosis was classified as absent, mild–moderate and severe (bridging necrosis or massive/submassive necrosis). The decision to initiate corticosteroids, dosing and route of administration was at the discretion of the physician in charge.

### 2.3 Statistical analysis

Quantitative variables are expressed as the mean and standard deviation (SD) or the median and interquartile range (first quartile-third quartile) when skewed. Normality was tested through distributional graphs and the Shapiro–Wilk’s test. Frequency counts and percentages were used for categorical data. Continuous variables were compared using parametric (t-test), and non-parametric tests (Mann–Whitney U test) when appropriate. Chi-squared and Fisher’s exact tests were used for categorical data. Cumulative incidences were calculated by the Kaplan–Meier method. To assess the impact of corticosteroids on 90-day transplant-free survival, we selected confounders based on prior knowledge instead of a data-driven approach. Thus, we adjusted for age, liver function (MELD score), sex and the presence of ascites and hepatic encephalopathy. We tested first-order interactions via a global likelihood ratio test. In the second stage, predictors of a poor outcome and lack of response to corticosteroids (death or liver transplantation within the 90 first days) were assessed by univariate and multivariate survival analysis with Cox’s regression. To minimise the risk of a type I error, we only considered variables that were readily available, reproducible and had a plausible pathophysiological link to the outcome of interest. Variables found to be significant (p<0.05) were considered in the final multivariate models. Finally, a nomogram model was developed and internally validated via bootstrapping with 200 resamples. The predictive performance of our nomogram was assessed through Harrell’s concordance index (C-index) and calibration plots. Additional information is detailed in supporting information.

Based on previous data and expert opinion, we performed the following exploratory analyses: (i) the value of dynamic changes in liver function to predict response to corticosteroids; (ii) the usefulness of MELD score as a single parameter and the accuracy of new multivariate predictive models relying on data obtained at days 3 and 7 of treatment; (iii) the benefits of adding histological findings in predicting the response to corticosteroids and (iv) the impact of corticosteroids on the risk of infection. These analyses included the development of new predictive models, which were constructed using the same approach as described above. For the histological analysis, we only included those samples obtained before the initiation of corticosteroids. For the infection risk analysis, patients diagnosed with infection at admission were excluded. Additionally, we assessed the performance in our population of the SURFASA score developed by De Martin et al. based on data from a multicenter French cohort of patients with AS-AIH: −6.80 + 1.92 × (D0-INR) + 1.94 × (Δ%3-INR) + 1.64 × (Δ%3-bilirubin).

All tests were two-tailed. Significance was set at p<0.05. Data were analysed at the promoting institution (Hospital Universitario Ramón y Cajal, Madrid, Spain) using STATA software 14.1 (StatCorp).

### 3 RESULTS

#### 3.1 Patient baseline characteristics

Of 253 patients with probable or definitive AS-AIH identified, 242 fulfilled all the selection criteria and presented 90-day follow-up data (Figure 1, study flowchart). The mean age of the 242 participants was 49.6 (16.8) years, 180 (74.4%) were female, 199 (82.2%) tested positive for ANA, smooth muscle antibodies (SMA), or LKM-1 and 156 (64.5%) showed increased serum IgG levels. The diagnosis
of AIH was considered probable or definitive in 130 (53.7%) and 112 (46.3%) patients, respectively.

On admission, all participants had impaired liver function with mean bilirubin of 14.5 (8.7) mg/dl, INR of 2.1 (0.8) and a MELD score of 24 (5). Ascites was present in 22 (21.5%), and 33 (13.6%) debuted with hepatic encephalopathy, which was graded III or IV in only 6 (2.5%). In consequence, 33 (13.6%) fulfilled the criteria for ALF on admission. Additional clinical and analytical baseline characteristics are provided in Table 1.

Two hundred and three patients (83.9%) received corticosteroids, with an initial mean dose of prednisolone of 58 (12) mg per day, mostly administered intravenously (59.1%). Most patients (79.8%) were treated with the standard dose of prednisolone of 1.0 mg/kg day, 18.2% with a dose of 0.5 mg/kg day, and only four patients received high doses (1.5 mg/kg/day) of methylprednisolone. The median time from admission to initiation of corticosteroids was 4 (2–8) days, and 90 (44.3%) patients were treated within the first 3 days of admission (early treatment). The 39 (16.1%) untreated patients had worse liver function on admission, as shown by higher bilirubin levels, INR, MELD scores and prevalence of hepatic encephalopathy. Laboratory, demographic, clinical and histological characteristics of treated and untreated patients are summarised in Table 1.

3.2 | Transplant-free survival and mortality

Of 72 patients with AS-AIH (29.8%) listed for emergency liver transplantation, 7 died on the waiting list, and 4 were delisted due to significant improvement. Thus, 61 patients (25.2%) were eventually transplanted. The median time from admission to wait listing was 8 (3–14) days, and 10 of 61 (16.4%) underwent liver transplantation within 3 days (median time from admission to transplantation 11 [5–26] days). Thirty-seven patients (15.3%) died within 90 days of admission, including 5 in the early postoperative period. The median time from admission to death was 29 (15–39) days. The overall 90-day transplant-free survival was 61.6% (95% CI 55.4–67.7%). In the subset of patients fulfilling ALF criteria on admission, this rate decreased to 21.1% (95% CI 5.5–35.9%).

3.3 | Effect of corticosteroid therapy on outcomes

Ninety-day transplant-free survival in patients treated with corticosteroids was significantly higher than in untreated patients (69.5% [95% CI 63.1–75.8] vs 20.5% [95% CI 7.2–33.8], p < 0.01) (Figure S1). As shown in Table 2, the benefit of corticosteroids was independent of sex, age, liver function (MELD score at baseline), and presence of hepatic encephalopathy on admission (HR 0.25 [95% CI 0.2–0.4], p < 0.01). We observed remission of hepatic encephalopathy in response to corticosteroids in 7 of 23 (30.4%) treated patients fulfilling ALF criteria on admission, yet this effect was not noted in any untreated patient. In contrast, the beneficial effect of corticosteroids on outcome was not observed in patients with any grade of ascites on admission (adjusted HR 0.61 [95% CI 0.3–1.3]; p = 0.22), which indicates a different effect of steroids depending on ascites presence (first-order interaction p < 0.01).

3.4 | Response to corticosteroid therapy

Treatment failed in 62 (30.5% [95% CI 24.2–36.9]) out of the 203 patients receiving corticosteroids: 32 patients (15.8%) were
TABLE 1  Clinical, histological and analytical characteristics at baseline

| Variable                              | All (n = 242) | Treated (n = 203) | Untreated (n = 39) | p value |
|---------------------------------------|---------------|-------------------|-------------------|---------|
| Age, years                            | 49.6 (16.8)   | 50.4 (16.9)       | 45.0 (15.6)       | 0.07    |
| Female sex                            | 180 (74.4%)   | 147 (72.4%)       | 33 (84.6%)        | 0.16    |
| Arterial hypertension                 | 42 (17.4%)    | 36 (17.7%)        | 61 (15.4%)        | 0.82    |
| Diabetes Mellitus                     | 14 (5.8%)     | 12 (5.9%)         | 2 (5.1%)          | 1.0     |
| Extrahepatic autoimmune disease      | 47 (19.4%)    | 42 (20.7%)        | 5 (12.8%)         | 0.38    |
| Alcohol consumption (>20–30 g/day)    | 11 (4.5%)     | 11 (5.4%)         | 0 (0%)            | 0.22    |
| Laboratory                            |               |                   |                   |         |
| Total bilirubin (mg/dl)               | 14.5 (8.7)    | 13.7 (7.6)        | 18.9 (12.1)       | 0.01    |
| Creatinine (mg/dl)                    | 0.82 (0.45)   | 0.81 (0.41)       | 0.89 (0.60)       | 0.28    |
| AST (IU/L)                            | 1373 (878)    | 1377 (879)        | 1359 (1073)       | 0.92    |
| ALT (IU/L)                            | 1309 (950)    | 1300 (928)        | 1358 (1073)       | 0.75    |
| Albumin (g/L)                         | 2.9 (0.6)     | 2.9 (0.6)         | 2.9 (0.5)         | 0.72    |
| Platelets × 10^3/mm³                  | 193 (83)      | 189 (81)          | 218 (89)          | 0.07    |
| INR                                   | 2.1 (0.8)     | 2.0 (0.6)         | 2.6 (1.3)         | <0.01   |
| MELD score                            | 24 (5)        | 23 (5)            | 27 (7)            | <0.01   |
| Clinical presentation                 |               |                   |                   |         |
| Ascites (any grade)                   | 52 (21.5%)    | 40 (19.7%)        | 12 (30.8%)        | 0.14    |
| Hepatic encephalopathy                |               |                   |                   |         |
| Absent                                | 209 (86.4%)   | 180 (88.7%)       | 29 (74.4%)        | 0.04    |
| Grade 1–2                             | 27 (11.2%)    | 19 (9.4%)         | 8 (20.5%)         |         |
| Grade 3–4                             | 6 (2.5%)      | 4 (2.0%)          | 2 (5.1%)          |         |
| Immunological features                |               |                   |                   |         |
| Seropositive                          | 199 (82.2%)   | 167 (82.3%)       | 32 (82.1%)        | 0.56    |
| ANA                                   | 176 (72.7%)   | 152 (74.9%)       | 24 (61.5%)        | 0.12    |
| LKM-1                                 | 12 (72.7%)    | 8 (3.9%)          | 4 (10.3%)         | 0.11    |
| SMA                                   | 88 (36.4%)    | 75 (36.9%)        | 13 (33.3%)        | 0.72    |
| IgG concentration                     | 2381 (1491)   | 2430 (1501)       | 2123 (832)        | 0.22    |
| IgG elevated (>1600 mg/dl)            | 156 (64.5%)   | 127 (62.6%)       | 29 (74.4%)        | 0.11    |
| Histological features                 |               |                   |                   |         |
| Number of patients                    | 155           | 134               | 21                |         |
| Interface hepatitis                   | 109 (70.3%)   | 99 (73.9%)        | 10 (47.6%)        | 0.02    |
| Portal inflammation (lymphoplasmacytic) | 84 (54.2%) | 77 (57.5%)       | 7 (33.3%)         | 0.06    |
| Emperipolesis                         | 32 (20.6%)    | 27 (20.1%)        | 5 (23.8%)         | 0.17    |
| Hepatocyte rosetting                  | 55 (35.5%)    | 50 (37.3%)        | 5 (23.8%)         | 0.45    |
| Centrilobular venulitis               | 108 (69.7%)   | 40 (29.9%)        | 7 (33.3%)         | 0.36    |
| Severe necrosis                       | 85 (54.8%)    | 68 (50.7%)        | 17 (81.0%)        | <0.01   |
| Severe fibrosis (grade 3–4)           | 35 (22.5%)    | 32 (23.8%)        | 3 (14.3%)         | 0.23    |

Note: Numbers represent absolute values or means with rates or standard deviations in parenthesis, respectively.

p < 0.05 are indicated in bold.

Abbreviations: ANA, antinuclear antibodies; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, International normalised ratio; LKM-1, liver kidney microsomal type 1; MELD, model for end-stage liver disease; SMA, smooth muscle antibodies.
transplanted, and 33 (16.3%) died, 3 of them after transplantation. In the univariate analysis, older age, male sex, worse liver function and the presence of ascites and hepatic encephalopathy recorded upon initiation of corticosteroids increased the risk of treatment failure. In Cox’s regression model, the factors emerging as predictors of a poor response were: older age (HR 1.02 [95% CI 1.0–1.1]; p < 0.01), MELD score (HR 1.2 [95% CI 1.1–1.3]; p < 0.01), the presence of hepatic encephalopathy (HR 2.3 [95% CI 1.3–4.2]; p < 0.01) and ascites (HR 2.1 [95% CI 1.2–3.8]; p < 0.01) at initiation of corticosteroids. In contrast, the early administration (<3 days after admission) and dose or route of corticosteroids had no impact on the primary outcome (Table 3). The mean dose of corticosteroids was similar in responders and non-responders (57 [13] vs 60 [11] mg/day), and the intravenous route was even more frequently used in non-responders (75 vs 54%). Neither the dose (p = 0.14) nor the administration route (p = 0.23) was selected as predictors of response during the multivariate modelling as detailed in Table S1.

A predictive nomogram based on the final model is provided in Figure 2A. The model showed good accuracy in estimating the 90-day risk of death or liver transplantation, with a C-index of 0.82 [95% CI 0.77–0.87] (Figure 3A). Calibration at days 7 and 14 of treatment, and days 30 and 90 post-admission was good as shown in (Figure 3B-E).

3.5 | Changes in liver function during corticosteroids

In a sensitivity analysis, changes in liver function at different time points after the onset of therapy were explored. Figure 4 shows that MELD significantly improved in responders as early as on day 3 of treatment (mean ΔMELD3–2.5 [2.5]), and further on days 7 (meanΔMELD7–5.0 [3.1]) and 14 of treatment (mean ΔMELD14–7.7 [4.2]). In contrast, mean MELD did not significantly change between initiation of corticosteroids and any of these time points in non-responders (ΔMELD3+0.8 [3.5]; ΔMELD7+0.4 [4.1]; Δ MELD14+0.8 [5.1], respectively). The 90-day transplant-free survival rates in patients without MELD improvement at treatment days 3 and 7 were as low as 38.5% and 18.8%, respectively (Figure S2). Interestingly, no statistically significant differences in the time-dependent AUC at 90-day transplant-free survival were found between the absolute value of MELD, %ΔMELD and ΔMELD on days 3 and 7 after treatment onset (Figure S3 and Table S2).

In our cohort, the best univariate predictor of response was the absolute value of MELD on day 7 of corticosteroids. The cut-off of 25 points showed a good specificity and negative predictive value (sensitivity 62.5% [95% CI: 47.0–75.8]; specificity 95.2% [95% CI: 89.9–97.8]; positive predictive value 80.6%; negative predictive value 89.9%).

Two multivariate predictive models based on information at days 3 and 7 of treatment were developed. One hundred and sixty-three of the 203 (80.3%) patients on corticosteroids were alive without liver transplantation on day 7 of treatment. In the multivariate analysis, MELD and the presence of hepatic encephalopathy and ascites on day 7 were independently related to treatment failure (Table 3). In consequence, a predictive nomogram based on this model is provided in Figure 3B. This model showed high accuracy (C-index 0.91 [95% CI: 0.87–0.95]) to predict a poor outcome (Figure S4). In contrast, the C index of the predictive model developed at day 3 of corticosteroids was slightly lower (0.85 [95% CI: 0.81–0.89]) (Table S3).

Incorporating ΔMELD on days 3 and 7 did not improve the performance of the models (Table S4).

In an additional analysis designed to examine the performance of the SURFASA score in our cohort,15 good discrimination capacity to identify non-responders was observed (AUC 0.85, 95% CI 0.78–0.91), but poor calibration (Hosmer–Lemeshow p < 0.001) (Figure S5).

3.6 | Predictive value of histological parameters

One hundred and fifty-five (64.1%) patients had a liver biopsy prior to the initiation of corticosteroids and were included in this sub-analysis. The median time from admission to liver biopsy was 3 (1–7) days, and most were performed by the transjugular route (77.4%). Main histological data are provided in Table 1. Histological findings on liver biopsy were critical for the diagnosis of AIH in 103 of the 242 patients (42.3%).

In our series, the only histological feature associated with a poor outcome in the univariate and multivariate analysis was the presence of severe necrosis (HR 5.67 [95% CI 1.6–6.2]; p < 0.01) but not the presence of severe liver fibrosis (HR 1.18 [95% CI 0.6–2.2]; p = 0.61) (Table S5). The inclusion of histological variables did not significantly change the predictive ability of the models (C index: 0.80).
Infection was present on admission in three patients and developed during hospitalisation in 40 (Table S6). Thirty-nine episodes of a bacteriologically proven infection were recorded in 34 patients. Urinary tract infection was the most frequent (9 episodes), followed by primary bacteremia (8 episodes) and spontaneous bacterial peritonitis (7 cases). Five patients developed a viral infection (4 CMV reactivation and 1 pneumonia due to H1N1 influenza virus), and 7 suffered invasive aspergillosis.

The cumulative incidence of infection during hospitalisation was 16.5% (95% CI 11.8–21.2), and the median time from admission was 18 (5–30) days. The incidence of infection was similar in patients treated and not treated with corticosteroids (Figure S6). As many as 12 of the 40 (30.0%) patients with infection had not received corticosteroids. Remarkably, the seven patients with invasive aspergillosis had all received corticosteroids (univariate $p = 0.24$) for at least 7 days (median time from treatment onset to the diagnosis of aspergillosis 18 [11–34] days). After adjusting by MELD score, age, sex, ascites and hepatic encephalopathy at admission, corticosteroid
therapy did not negatively impact the risk of infection (HR 0.75 [95% CI 0.3–2.0]; \( p = 0.57 \)) (Table S6). Among treated patients, a worse liver function, higher dose of corticosteroids and the presence of ascites and encephalopathy at treatment onset increased the risk of infection in the univariate analysis (Table S7). In Cox’s regression model, only MELD score (HR 1.16 [95% CI 1.1–1.3]; \( p < 0.01 \)), and ascites (HR 2.12 [95% CI 1.0–4.4]; \( p = 0.04 \)) at treatment onset emerged as predictors of infection. The model showed moderate accuracy in estimating the infection risk, with a C-index of 0.74 (95% CI 0.65–0.84).

**FIGURE 2** Nomogram to estimate the risk of treatment failure. (A) Nomogram at the initiation of treatment; (B) nomogram at day 7 of treatment. To use the nomogram, we first draw a line from each parameter value to the score axis for the score. The points for all the parameters are then added. Finally, a line from the total score points axis is drawn to the lower line of the nomogram to obtain the predicted 90-day transplant-free survival. MELD: Model for end-stage liver disease.
In this nationwide retrospective study, we analysed predictive factors associated with a poor response to corticosteroid treatment in the largest series of patients with AS-AIH examined to date. Our findings revealed that: (i) corticosteroids improved 90-day transplant-free survival, but up to one-third of patients were unresponsive to them, (ii) older patients with poor liver function, ascites or encephalopathy at the initiation of treatment were unlikely to respond, (iii) a lack of improvement in liver function after 7 days of corticosteroids was highly predictive of treatment failure and (iv) prolonging corticosteroids in non-responders emerged as unlikely to modify the course of events and should be avoided in patients listed for liver transplantation.
Corticosteroids remain the cornerstone treatment of AIH as remission rates approach 60–80%.15,21,22 However, their beneficial effects in patients with acute and severe presentations have been a matter of debate. Our results definitively confirm that the usefulness of this treatment extends to this scenario, in which corticosteroids were found to raise transplant-free survival by 3.4-fold. The survival rate of non-responders was as low as those untreated, which highlights a need for accurate scores for early response prediction. As independent predictors of treatment failure, we identified an older age, high MELD, encephalopathy and ascites at treatment initiation. Our results from the largest cohort to date are consistent with the findings of others, confirming that poor liver function and encephalopathy are linked to higher mortality.15 In fact, patients with ALF showed the worst response to treatment as their transplant-free survival was as low as 21.1%. However, in up to one-third, encephalopathy was reversed by treatment. Thus, the isolated presence of encephalopathy should not preclude corticosteroid use, unless other factors are present. Specifically, ascites was found to be a strong modifier of the effect of corticosteroids, as supported by the interaction effect of both variables on transplant-free survival. Distinctively, our study incorporates a nomogram that can estimate the survival probability of an individual before initiation of therapy with a C-index of 0.82. The nomogram allows the assessment of the readily available prognostic variables identified in a single time point and as early as possible in the course of the disease, which are criteria of quality of a predictive model. Our nomogram can be used shortly after admission to accurately identify a patient unlikely to respond to treatment and represents a quantitative tool for clinical decision-making at the bedside. Patients can then be considered for an early referral or diagnostic work-up for liver transplantation.

Despite the accuracy of our nomogram, patients with AS-AIH and a low probability of response should receive corticosteroids, as avoiding this treatment was linked to the worst prognosis (transplantation within 3 days of corticosteroid treatment was associated with an AUC of 0.93). The SURFASA score tested on our cohort showed good accuracy to identify treatment failure at day 3 of treatment, but rather a poor calibration probably reflecting overfitting of the model due to the smaller size of the French cohort.15 The accuracy of the scores used on days 3 or 7 of treatment in the French study could not be compared because of missing data. We, nevertheless, identified the MELD on day 7 as a powerful bedside tool to identify patients likely to show poor survival. The better performance of the model at day 7 is probably due to the greater prognostic information provided by adding dynamic variables. We cannot completely discard the contribution to this observation of a smaller sample size due to the loss of high-risk patients that did not reach the day 7 time-point. However, we consider this reason unlikely as the number of patients that reached day 7 with complete clinical information was quite large, and the performance of the model at day 3 was slightly worse although more patients reached this time point. Inclusion in our model of variables with predictive meaning at a single time point instead of the change in their value from admission (∆values) was intended to facilitate its use for clinicians because incorporating ∆MELD in multivariable models did not improve their prognostic yield. Remarkably, despite the high accuracy of the assessment of liver function on days 3 and especially 7 of therapy to predict a poor outcome, the predictive value of the nomogram including only baseline data was similar.

Our study revealed that a low titre or lack of autoantibodies and IgG normality are not uncommon in AS-AIH, making liver biopsy necessary to fulfill standard simplified diagnostic criteria, as occurred in 42.3% of the cases in our series.8 These findings support current EASL clinical practice guidelines that consider liver biopsy a requirement for AIH diagnosis, and that it should be performed before starting treatment.2 More controversy exists regarding the value of histological findings to predict the response to corticosteroids. Findings such as massive necrosis and central perivenulitis have been related to a worse outcome in most studies.6,27 The predictive value of the fibrosis stage is under discussion. In our study, severe liver necrosis, but not fibrosis stage, was noted to increase the risk of treatment failure. Interestingly, the inclusion of histological variables did not significantly augment the accuracy of the model based on variables obtained before starting corticosteroids.

The dose, route of administration and timing of onset of corticosteroids have also been a matter of debate.2,5,15 Most of our patients received the recommended dose of 1 mg/kg day of prednisolone by the intravenous route.2 In agreement with the results of De Martin et al., the response to steroids in our series was independent of dose or administration route.15 However, no firm conclusions can either be drawn in this regard as our cohort was also retrospective in nature and decisions regarding dose and route of corticosteroids were arbitrarily taken by the respective practitioner. Of note, we found no difference in response between “early” (<3 days) or “late” initiation of steroids, indicating sufficient time for an extensive diagnostic work-up (including the ruling-out of infection) after admission.
Infection is a concern in patients with severe liver insufficiency undergoing steroid treatment, as an active infection could jeopardise liver transplantation.\textsuperscript{13,25,27–31} Corticosteroids alone did not increase the bacterial infection risk. This was supported by the similar rates of infection recorded in patients on and not on steroids, and by the lack of independent association between corticosteroids and infection risk detected in the multivariate analysis. In effect, the infection risk in our study was related to the severity of liver insufficiency, as it was highest in patients with high MELD and ascites, which also emerged as independent factors predictive of a non-response to steroids. Similarly, bacterial infection risk in patients with severe alcoholic hepatitis is more closely related to a non-response to corticosteroids than the therapy itself.\textsuperscript{12,32}

However, our results suggest an association between prolonged corticosteroids and systemic fungal infection. Invasive aspergillosis, a condition that compromises transplantation,\textsuperscript{32} was detected in seven patients, all of whom had been on corticosteroids for at least 7 days. Physicians should be aware of this risk and avoid extending corticosteroids beyond 7 days in non-responders, especially in liver transplantation candidates.

We here present the largest published dataset on prognosis and response to therapy in AS-AIH. Additionally, our complete laboratory data for 3 and 7 days of treatment allowed us to compare the performance accuracy of the models at both time points. To our knowledge, this is the first study to provide a prediction nomogram to anticipate the response to corticosteroids at disease presentation. We should acknowledge several limitations. Firstly, in the final analysis, we included all patients diagnosed with AS-AIH, even those with severe liver fibrosis and/or cirrhosis detected on liver biopsy, possibly representing a different population. According to current guidelines, patients with acute presentations of AIH are included in the definition of ALF and are considered candidates for emergency liver transplantation, despite the possibility of underlying advanced chronic liver disease.\textsuperscript{16,18} However, in the sub-analysis performed to overcome this limitation in patients with complete histological information prior to corticosteroids, the treatment response was independent of the fibrosis stage. Finally, the retrospective nature of this study is an intrinsic limitation that makes it difficult to identify patients warranting a corticosteroids trial and those who should be directly referred for liver transplantation. While we tried to adjust for confounding factors by multivariate regression analysis, residual confounders due to unknown or unmeasured covariates may not be completely ruled out. Consequently, the prognostic models developed need further prospective and external validation.

Our study provides support for current clinical recommendations that are based on expert opinion. Its findings indicate a survival benefit of corticosteroids in AS-AIH, and a trial of this therapy is warranted in most patients, even those with encephalopathy. Response to therapy should be assessed at treatment onset and after 3 days, or better still 7 days, to early identify patients likely to be non-responders. Prolonging treatment in non-responders beyond this time point should be avoided, especially in transplantation candidates, as it is unlikely it will modify the disease course yet may increase the risk of invasive aspergillosis. Importantly, a nomogram including older age, high MELD and presence of encephalopathy and ascites accurately identify newly admitted patients unlikely to respond to steroids thus expediting their referral or work-up for liver transplantation.

ACKNOWLEDGEMENT
Declaration of personal interests: The authors have no conflicts of interest pertaining to this work and all authors have fulfilled the conflict of interest statement.

AUTHOR CONTRIBUTIONS
Luis Téllez: Conceptualization (lead); data curation (lead); formal analysis (lead); investigation (lead); methodology (lead); project administration (lead); resources (lead); supervision (lead); validation (lead); visualization (lead); writing – original draft (lead); writing – review and editing (lead).
Eugenia Sánchez Rodríguez: Conceptualization (equal); data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); project administration (equal); resources (equal); supervision (equal); validation (equal); visualization (equal); writing – original draft (equal); writing – review and editing (equal).
Enrique Rodríguez de Santiago: Conceptualization (equal); data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); project administration (equal); resources (equal); software (equal); supervision (equal); validation (equal); visualization (equal); writing – original draft (equal); writing – review and editing (equal).
Laura Patricia Llovet: Data curation (equal).
Ana Gómez Outomuro: Data curation (equal).
José Ignacio Fortea: Data curation (equal). Data curation (equal).
Laura M. García-Eliz: Data curation (equal).
José Ignacio Fortea: Data curation (equal). Data curation (equal).
María García-Eliz: Data curation (equal).
Patricia Álvarez López: Data curation (equal).
María García-Eliz: Data curation (equal).
Yolanda Sánchez-Torrijos: Data curation (equal).
José Ignacio Fortea: Data curation (equal). Carlos Ferre Arcalí: Data curation (equal).
Carlos Ferre Arcalí: Data curation (equal).
Manuel Rodríguez-Peralvast: Data curation (equal).
Marta Abadia: Data curation (equal).
Javier Crespo: Data curation (equal); validation (equal).
José Luis Calleja: Data curation (equal); validation (equal).
José Luis Calleja: Data curation (equal); validation (equal).
María Carmen Berenguer Hayme: Data curation (equal); validation (equal).
Manuel Herrández-Guerra: Data curation (equal); validation (equal).
Manuel Herrández-Guerra: Data curation (equal); validation (equal).
Mar Riveiro-Barciela: Data curation (equal); visualization (equal).
Magdalena Salcedo: Data curation (equal); validation (equal).
Manuel Rodríguez: Data curation (equal); visualization (equal).
María-Carlosa Londoño: Data curation (equal); validation (equal).
Agustín Albillos: Conceptualization (lead); data curation (lead); formal analysis (lead); funding acquisition (lead); investigation (lead); methodology (lead); project administration (lead); resources (lead); supervision (lead); validation (lead); visualization (lead); writing – original draft (equal); writing – review and editing (lead).

DATA AVAILABILITY STATEMENT
Data, analytic methods, and study materials will be available to other researchers upon request to the corresponding author.
REFERENCES

1. Manns MP, Czaja AJ, Gorham JD, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193–213. doi:10.1002/hep.23584

2. European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004. doi:10.1016/j.jhep.2015.06.030

3. Lohse AW, Mieli-Vergani G. Autoimmune hepatitis. J Hepatol. 2011 Jul;55(1):171–82. doi:10.1016/j.jhep.2010.12.012

4. Takahashi H, Zeniya M. Acute presentation of autoimmune hepatitis: does it exist? A published work review. Hepatol Res. 2011 Jun;41(6):498–504. doi:10.1111/j.1872-034X.2011.00808.x

5. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and Management of Autoimmune Hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671–722. doi:10.1002/hep.31065

6. Stravitz RT, Lefkowitch JH, Fontana RJ, Gershwin ME, Leung PS, Sterling RK, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology. 2011;53(2):517–26. doi:10.1002/hep.24080

7. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929–38.

8. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt JA, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169–76. doi:10.1002/hep.22322

9. Yeoman AD, Westbrook RH, Zen Y, Bernal W, Al-Chalabi T, Wendon JA, et al. Prognosis of acute severe autoimmune hepatitis (AS-AH): the role of corticosteroids in modifying outcome. J Hepatol. 2014;61(4):876–82. doi:10.1016/j.jhep.2014.05.021

10. Moenne-Loccoz R, Severac F, Baumert TF, Habersetzer F. Usefulness of corticosteroids as first-line therapy in patients with acute severe autoimmune hepatitis. J Hepatol. 2016;65(2):444–6. doi:10.1016/j.jhep.2016.03.023

11. Sonthalia N, Rathi PM, Jain SS, Surude RG, Mohite AR, Pawar SV, et al. Natural history and treatment outcomes of severe autoimmune hepatitis. J Clin Gastroenterol. 2017;51(6):548–56. doi:10.1097/MCG.0000000000000850

12. Louvet A, Wartel F, Castel H, Dharnarcy S, Hollebecque A, Canva-Delambre V, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology. 2009;137(2):541–8. doi:10.1053/j.gastro.2009.04.062

13. Fujiwara K, Yasui S, Yonemitsu Y, Arai M, Kanda T, Fukuda Y, et al. Analysis of infectious complications and timing for emergency liver transplantation in autoimmune acute liver failure. J Hepatobiliary Pancreat Sci. 2016;23(4):212–9. doi:10.1002/jbp.326

14. Karkhanis J, Verna EC, Chang MS, Stravitz RT, Schilsky M, Lee WM, et al. Steroid use in acute liver failure. Hepatology. 2014;59(2):612–21. doi:10.1002/hep.26678

15. De Martin E, Coilly A, Chazouillères O, Roux O, Peron JM, Houssel-Debry P, et al. Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: the SURFAS score. J Hepatol. 2021;74(6):1325–34. doi:10.1016/j.jhep.2020.12.033

16. European Association for the Study of the Liver. EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047–81. doi:10.1016/j.jhep.2016.12.003

17. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147(8):W163–94. doi:10.1037/0003-4819-147-8.200.710.160.00010-w1

18. European Association for the Study of the Liver. EASL clinical practical guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. doi:10.1016/j.jhep.2018.03.024. Epub 2018 Apr 10. Erratum in: J Hepatol. 2018 Nov;69(5):1207. PMID:29653741.

19. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–71. doi:10.1053/he.2000.5852

20. Bedossa P. Presentation of a grid for computer analysis for compi- lation of histopathologic lesions in chronic viral hepatitis C. cooperative study of the META VIR group. Ann Pathol. 1993;13(4):260–5. French

21. Zhang C, Wu SS, Dong XQ, Wu Z, Zhao H, Wang GQ. The efficacy and safety of different doses of glucocorticoid for autoimmune hepatitis: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(52):e18313.

22. Zachou K, Arvanitis P, Azariadis K, Lygoura V, Gatsellis NK, Lyberopoulou A, et al. Prompt initiation of high-dose i.v. cortici- steroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. Hepatol Res. 2019;49(1):96–104. doi:10.1111/hepr.13252

23. Villamil AG, Ciscato P, Eduardo M, Bustos D, Giunta D, Bandi JC, et al. Fulminant autoimmune hepatitis: clinical presentation, outcome and prognostic factors. Am J Transpl. 2005;5(Suppl. 11):278.

24. De Martin E, Coilly A, Ichai P, Samuel D, Duclos-Vallée JC. The role of corticosteroids in acute-severe autoimmune hepatitis is still highly debatable. J Hepatol. 2015;63(4):1041–2. doi:10.1016/j.jhep.2015.04.032

25. Verma S, Maheshwari A, Thuluvath P. Liver failure as initial pre- sentation of autoimmune hepatitis: clinical characteristics, pre- dictors of response to steroid therapy, and outcomes. Hepatology. 2009;49(4):1396–7. doi:10.1002/hep.22894

26. Yeoman AD, Westbrook RH, Zen Y, Maninchetta P, Portmann BC, Devlin J, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology. 2011;53(3):926–34. doi:10.1002/hep.24141

27. Mandzabal M, Marciano S, Videla MG, Anders M, Zerega A, Delcambre V, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology. 2009;137(2):541–8. doi:10.1053/j.gastro.2009.04.062

28. Rahim MN, Miquel R, Heneghan MA. Approach to the patient with acute severe autoimmune hepatitis. JHEP Rep. 2020;2(6):100149. doi:10.1016/j.jhepr.2020.100149

29. Rolando N, Harvey F, Brahmi J, Philpott-Howard J, Alexander G, Casewell M, et al. Fungal infection: a common, unrecognised compi- lation of acute liver failure. J Hepatol. 1991;12(1):1–9. doi:10.1016/0168-8278(91)90900-v
30. Rolando N, Philpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis. 1996;16(4):389–402. https://doi.org/10.1055/s-2007-1007.252

31. Vaquero J, Polson J, Chung C, Helenowski I, Schiodt FV, Reisch J, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology. 2003;125(3):755–64. https://doi.org/10.1016/s0016-5085(03)01051-5

32. Louvet A, Naveau S, Abdelnour M, Ramond MJ, Díaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45(6):1348–54. https://doi.org/10.1002/hep.21607

SUPPORTING INFORMATION
Additional supporting information will be found online in the Supporting Information section.

How to cite this article: Téllez L, Sánchez Rodríguez E, Rodríguez de Santiago E, Llovet L, Gómez-Outomuro A, Díaz-Fontenla F, et al. Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study. Aliment Pharmacol Ther. 2022;56:131–143. https://doi.org/10.1111/apt.16926